GAITHERSBURG, Md. & HYDERABAD, India--(Business Wire)--
Ocimum Biosolutions today announced the issuance of U.S. Patent
No. US 7,415,358 B2 entitled 'Molecular toxicology modeling'. The
patent describes elucidation of the global changes in gene expression
and identification of toxicity markers in tissues or cells exposed to
a known renal toxin. The genes can be used as toxicity markers in drug
screening and toxicity assays. The invention includes a database of
genes characterized by toxin-induced differential expression that is
designed for use with microarrays and other solid-phase probes.
Anu Acharya, CEO, Ocimum Biosolutions, said, "We have consistently
been in the forefront of Genomics Innovation over many years and this
patent reiterates our strong commitment to continue as a leader in
this space."
"Ocimum Biosolutions (Gene Logic) will continue to innovate
through areas like Genotyping, Gene Expression, PCR and other data
validation approaches to bring the latest and most promising
technologies to our pharmaceutical and biotech clients who have chosen
us as their preferred partner in their discovery pursuit for more than
a decade," added Anu Acharya.
About Ocimum Biosolutions:
Ocimum Biosolutions (and its subsidiary company Gene Logic) is a
leading integrated genomics company providing comprehensive genomic
reference databases, life science lab information management
solutions, GLP-compliant microarray services and essential research
consumables. Over 2/3rd of the top 25 pharma companies, leading
research institutes and emerging biotech companies worldwide have
chosen Ocimum as their preferred outsourcing partner and utilize
Ocimum's expertise for understanding underlying mechanisms of
diseases, discovery and prioritization of gene targets and biomarkers.
Gene Logic is a preferred outsourcing partner for providing
integrated biorepository and genomic services for several global
pharmaceutical companies. Gene Logic's global infrastructure,
standardized procedures, capacity, expertise and highly skilled staff
support drug development programs from pre-clinical target development
and toxicogenomic assessment to clinical biomarker identification and
patient stratification. In creating the world's largest commercial
gene expression databases - BioExpress(R) and ToxExpress(R), Gene
Logic has expertise and capabilities that are unparalleled in the
genomic services industry. Gene Logic provides multiple GLP-compliant
platforms for gene expression and SNP genotyping data generation, full
biorepository and genomic services support for the Genetic Alliance,
which is an umbrella organization representing approx. 600 genetic
advocacy groups. Besides providing the physical infrastructure for
storing thousands of biological samples, Gene Logic provides services
to assist sample accrual, IRB approvals, CRO training, sample
collection, clinical data capture and management.
For more information, please visit www.genelogic.com and
www.ocimumbio.com.
Ocimum Biosolutions
Customer & Media:
Ashwin Sivakumar, +91 40-66627200
Director - Marketing Alliances and Outreach
pr@ocimumbio.com
or
Investors:
Chief Executive Officer
ceo@ocimumbio.com
Copyright Business Wire 2008
